DexCom (NASDAQ:DXCM) Sees Unusually-High Trading Volume - Time to Buy?

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) shares saw unusually-high trading volume on Friday . Approximately 1,644,516 shares were traded during mid-day trading, a decline of 26% from the previous session's volume of 2,209,038 shares.The stock last traded at $78.34 and had previously closed at $80.09.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of research reports. JPMorgan Chase & Co. raised their target price on shares of DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, October 25th. StockNews.com downgraded DexCom from a "buy" rating to a "hold" rating in a report on Saturday, November 2nd. Sanford C. Bernstein boosted their price objective on DexCom from $82.00 to $86.00 and gave the stock an "outperform" rating in a research note on Friday, October 25th. Wells Fargo & Company raised their target price on DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a report on Wednesday, December 11th. Finally, Oppenheimer dropped their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, DexCom has an average rating of "Moderate Buy" and an average price target of $98.00.

DexCom Stock Down 2.9 %

The firm has a market cap of $30.37 billion, a P/E ratio of 46.56, a PEG ratio of 2.36 and a beta of 1.12. The firm's 50-day moving average price is $76.93 and its 200 day moving average price is $79.30. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On DexCom

A number of hedge funds and other institutional investors have recently bought and sold shares of DXCM. Versant Capital Management Inc bought a new stake in shares of DexCom in the 4th quarter worth approximately $25,000. Riverview Trust Co increased its position in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after buying an additional 232 shares during the period. RPg Family Wealth Advisory LLC bought a new stake in DexCom in the third quarter valued at $57,000. Covestor Ltd boosted its holdings in shares of DexCom by 53.7% during the third quarter. Covestor Ltd now owns 959 shares of the medical device company's stock valued at $64,000 after acquiring an additional 335 shares during the period. Finally, Blue Trust Inc. grew its position in shares of DexCom by 101.9% during the third quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company's stock worth $119,000 after acquiring an additional 898 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.